HOME >> MEDICINE >> NEWS
Overactive bladder episodes completely controlled in 40 percent of elderly patients treated with once-a-day Oxybutynin

Elderly patients suffering from overactive bladder can significantly and safely reduce the symptoms of their condition by taking a once-a-day, extended-release formulation of oxybutynin chloride (Ditropan XL®), according to a study conducted by the Cleveland Clinic Foundation scheduled for presentation at the 2000 Annual Scientific Meeting of the American Geriatrics Society.

In the study, 40 percent of patients age 65 and older taking extended-release oxybutynin reported no incontinence episodes, while the average reduction in the weekly number of incontinence episodes for the elderly patients in the study was 82 percent.

"We found that elderly patients not only benefit by significantly reducing or eliminating their incontinence episodes when taking the extended-release formulation of oxybutynin, they also can do so safely and tolerate the drug very well. This is good news for this patient population, which frequently must deal with taking multiple medications and experiencing worrisome side effects," said Rodney Appell, M.D., study author and head, Section of Voiding Dysfunction and Female Urology at the Cleveland Clinic Urological Institute.

Overactive bladder is a common and chronic condition that affects an estimated 17 million Americans. The condition is characterized by urge urinary incontinence (sudden and involuntary loss of bladder control resulting in wetting accidents), urgency (the urgent need to empty the bladder) and frequency (frequent urination). Ditropan XL is the first and only once-a-day treatment for overactive bladder approved by the FDA and is marketed by ALZA Corporation and UCB Pharma.

For the study, investigators analyzed three clinical trials comparing different doses of extended-release and immediate-release oxybutynin in 159 patients older than 65 and in 261 patients age 18 to 65. All of the 420 patients suffered from overactive bladder.

During the clinical trials, researchers adjusted the
'"/>

Contact: Jim Armstrong, Cleveland Clinic
216-444-9455
Porter Novelli
19-May-2000


Page: 1 2 3

Related medicine news :

1. Overactive bladder symptoms affect sexual activity of women says Univ. of Pittsburgh study
2. New substance that improves the photodetection of bladder cancer gains market approval
3. Study examines three-day antibiotic regimens for treating bladder infection in women
4. New study tests amitriptyline for painful bladder syndrome
5. New test improves detection of bladder cancer
6. Faster, less expensive test proven more effective in detecting bladder cancer
7. Promise of bladder pacemaker for people with spinal cord injury
8. Use of estrogen therapy may increase risk for gallbladder disease
9. FDA approves Enablex for treatment of overactive bladder
10. Long-term data show benefit of DETROL LA as first-line therapy for overactive bladder
11. Scientists begin validation study of test to detect recurrence of bladder cancer

Post Your Comments:
(Date:2/27/2015)... On February 24 2015, Harper’s Bazaar Magazine posted an ... details the development of RT001, a form of topical botulinum ... trials. For those afraid of needles, the idea of a ... if the drug ultimately gets FDA approval it will be ... , “As the article notes, the size of the ...
(Date:2/27/2015)... 27, 2015 Adding to its ... pharmaceuticals, Benedict Advertising & Marketing has added Sedation ... The company’s patented NITROUSEAL® N20 closed mask and ... of sedation. , Sedation Systems, http://www.sedationsystems.com ... a new level, though it focuses primarily on ...
(Date:2/27/2015)... NY (PRWEB) February 27, 2015 The winter ... mold growth and expansion. When mold grows, it can be ... be sure to avoid the consequences of mold growth with ... Long Island, is offering tips on the best ways to ... wet season, which makes perfect conditions for mold to thrive. ...
(Date:2/27/2015)... Vancouver, BC (PRWEB) February 27, 2015 ... exciting overnight deals for couples who wanted to spend ... with the opportunity to get a jump on Valentine’s ... meal and stay in one of their luxurious rooms. ... on February 13, inviting guests for a mouthwatering 3 ...
(Date:2/27/2015)... Florida Hospital North Pinellas is being ... Gold Plus hospital. In order to receive the award, ... to all Get With The Guidelines - Stroke Quality ... and achieved 75-percent or higher compliance with six of ... These are reporting initiatives to measure quality of care. ...
Breaking Medicine News(10 mins):Health News:Is Topical Botox the Next Big Thing? 2Health News:Benedict Advertising & Marketing Signs Sedation Systems 2Health News:Enviro-Test Offers Tips for Winter Mold Prevention 2Health News:Victorian Hotel Celebrated Valentine’s Day in 2015 With Unique Overnight Deal 2Health News:Florida Hospital North Pinellas Receives Get With The Guidelines - Stroke Gold Plus Quality Achievement Award 2
(Date:2/27/2015)... Feb. 27, 2015  PTC Therapeutics, Inc. (NASDAQ: ... reported financial results for the fourth quarter and full ... was a transformative year for PTC. We are now ... developing RNA-targeted therapies in the rare disease space," stated ... Inc. "We are proud to bring the first treatment ...
(Date:2/27/2015)... 2015  Bionik Laboratories Corp. (OTC:DWTPD), a ... it acquired Bionik Laboratories, Inc., a Toronto ... to qualified accredited investors of units consisting of its ... approximately $6.2 million. Shares of the Company,s common stock ... under the symbol "DWTPD" until FINRA,s approval of the ...
(Date:2/26/2015)... -- RnRMarketResearch.com adds Corneal Ulcers - ... its store. This report p provides an overview ... The report "Corneal Ulcers - Pipeline Review, H2 2014" provides ... Ulcers. Corneal Ulcers are primarily result of the ... & fungal infections. The symptoms of the corneal ...
Breaking Medicine Technology:PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5
Cached News: